Healthcare / BiotechnologyNasdaqCM
$3.86
+0.36 (+10.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-30.3M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$59M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-110.4%
↓Gross Margin
62.7%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-10661.2%
FCF / Net income
1.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $813455.0 · net income $-45.3M · FCF $-86.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $813455.00 | $813455.00 | $57336.00 | $3787.00 | — | $14.0M | $2.0M | — | — | — | — |
| Net Income | $-45.3M | $-45.3M | $-49.8M | $-27.3M | $-28.0M | $-12.8M | $-19.8M | $-21.2M | $-17.3M | $-5.1M | $-3.5M |
| EBITDA | $-43.8M | $-43.8M | $-46.2M | $-24.1M | $-26.3M | $-12.8M | $-19.7M | $-21.3M | $-17.2M | $-5.1M | $-3.5M |
| EPS | — | — | -59.81 | -53.15 | -66.40 | -39.20 | -75.20 | — | — | — | — |
| Gross Margin | 62.7% | 62.7% | -6749.5% | -322.6% | — | 88.6% | 60.0% | — | — | — | — |
| Operating Margin | -2333.4% | -2333.4% | -65456.8% | -670885.8% | — | -93.0% | -989.5% | — | — | — | — |
| Net Margin | -5570.6% | -5570.6% | -86888.6% | -719859.9% | — | -91.3% | -988.5% | — | — | — | — |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.21 | 0.21 | -0.86 | 1.79 | 0.59 | — | — | — | — | — | — |
| Current Ratio | 1.97 | 1.97 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-86.7M | $-86.7M | $-30.3M | $-27.8M | $-26.0M | $-22.1M | $-6.6M | $-19.1M | $-13.1M | $-4.7M | $-3.2M |
| Returns | |||||||||||
| ROE | -110.4% | -110.4% | 380.4% | -302.9% | -162.5% | -62.4% | -129.2% | -180.2% | -102.2% | -100.8% | -117.4% |
| Valuation | |||||||||||
| P/B | 0.82 | 0.82 | — | 8.53 | 3.51 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 1318.8% | 1318.8% | 1414.0% | — | — | 600.0% | — | — | — | — | — |
| EPS Growth | — | — | -12.5% | 20.0% | — | 47.9% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+131.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-59.81 → n/d
Residual
+131.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.